Publication number: 20220118121
Abstract: The present invention relates to a compound of formula (1), and to a complex comprising said compound and a radionuclide, and to the respective pharmaceutical composition, the compound having the following structure or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is H or —CH3, preferably H, wherein R2, R3 and R4 are independently of each other, selected from the group consisting of —CO2H, —SO2H, —SO3H, —OSO3H, —PO2H, —PO3H and —OPO3H2, Q1 is selected from the group consisting of alkylaryl, arylalkyl, aryl, alkylheteroaryl, heteroarylalkyl and heteroaryl, Q2 is selected from the group consisting of aryl, alkylaryl, arylalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl and alkylheteroaryl, A is a chelator residue derived from a chelator selected from the group consisting of 1,4,7,10-tetraazacyclododecane-N,N?,N?,N??-tetraacetic acid (=DOTA), N,N?-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N?-diacetic acid, 1,4,7-triazacyclononane-1,4,7-triacetic acid (=NOTA),
Type:
Application
Filed:
February 14, 2020
Publication date:
April 21, 2022
Inventors:
Matthias Eder, Ann-Christin Baranski, Michael Eisenhut, Uwe Haberkorn
